GPRC5D; MGC129713; MGC129714; orphan G-protein coupled receptor
Immobilized Human GPRC5D VLP at 5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-GPRC5D Antibody, hFc Tag with the EC50 of 11.8ng/ml determined by ELISA. |
Biotinylated Human GPRC5D VLP captured on SA Chip can bind Anti-GPRC5D antibody, hFc with an affinity constant of 0.30 nM as determined in SPR assay (Biacore T200). |
KACTUS products are validated for purity and bioactivity using analytical techniques such as Bis-Tris, HPLC, ELISA, and SPR. Our proteins are designed and manufactured in-house using our SAMS protein engineering platform and high-standard manufacturing facilities.
Process Validation
We monitor the entire production process to ensure expression conditions are optimal for that specific protein. This includes monitoring (1) growth of host cells, (2) expression of the target gene, and (3) purification of the recombinant protein. Moreover, we've optimized the expression process to minimize the presence of contaminants that can affect the purity or activity of the final product.
Analytical Testing
PURITY KACTUS ensures the purity of each recombinant protein using HPLC and Bis-Tris Page. Additionally, we quantify the level of impurities, such as host cell proteins, endotoxin, and host cell DNA in the final product.
ACTIVITY We analyze the potency of our recombinant proteins by measuring in vitro activity, such as its ability to bind to its target molecule via ELISA or SPR assay.
CONSISTENCY Our team tests for batch-to-batch consistency to ensure stable bioactivity across lots. Additionally, we assess stability of our proteins by measuring degradation over time and resistance to environmental stress factors, such as temperature and pH changes.
Recently viewed
